Treatment of the common cold with troxerutin

APMIS

Volumn 112, Issue 9, 2004, Pages 605-11

  Turner, Ronald B ^a,d   Fowler, Sandra L ^b   Berg, Kurt ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Anti edema; Common cold; Rhinitis; Treatment; Troxerutin

Indexed keywords

FLAVONOID; GLUCONATE ZINC; RUTOSIDE; TROXERUTIN;

ADULT; AGED; ARTICLE; CAPILLARY PERMEABILITY; CHILL; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HUMAN; LOZENGE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH DISEASE; NAUSEA; NOSE OBSTRUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SNEEZING; SORE THROAT; SYMPTOMATOLOGY; TASTE; XEROSTOMIA;

EID: 11144314771     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm1120908.x     Document Type: Article

References (36)

1. Gwaltney JM Jr, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. J Am Med Assoc 1967;202:494-500.
2. Rao SS, Hendley JO, Hayden FG, Gwaltney JM Jr. Symptom expression in natural and experimental rhinovirus colds. Am J Rhinol 1995;9:49-52.
3. Turner RB, Witek TJ Jr, Riker DK. Comparison of symptom severity in natural and experimentally induced colds. Am J Rhinol 1996;10:167-172.
4. Igarashi Y, Skoner DP, Doyle WJ, White MV, Fireman P, Kaliner MA. Analysis of nasal secretions during experimental rhinovirus upper respiratory infections. J Allergy Clin Immunol 1993;92:722-31.
5. Douglas RG Jr. Pathogenesis of rhinovirus common colds in human volunteers. Ann Otol Rhinol Laryngol 1970;79:563-71.
6. Vanscheidt W, Rabe E, Naser-Hijazi B, Ramelet AA, Partsch H, Diehm C, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa 2002;31:185-90.
7. Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiology 2002;53:257-63.
8. Incandela L, Cesarone MR, DeSanctis MT, Belcaro G, Dugall M, Acerbi G. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 2002;7 Suppl 1:S11-5.
9. Incandela L, Belcaro G, Renton S, DeSanctis MT, Cesarone MR, Bavera P, et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002;7 Suppl 1:S7-10.
10. Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Griffin M, Ippolito E, et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther 2002;7 Suppl 1:S21-4.
11. Cesarone MR, Belcaro G, Incandela L, Geroulakos G, Griffin M, Lennox A, et al. Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trial. J Cardiovasc Pharmacol Ther 2002;7 Suppl 1:S17-20.
12. Clement DL. Management of venous edema: insights from an international task force. Angiology 2000;51:13-7.
13. Rehn D, Hennings G, Nocker W, Diebschlag W. Time course of the anti-oedematous effect of O-(beta-hydroxyethyl)-rutosides in healthy volunteers. Eur J Clin Pharmacol 1991;40:625-7.
14. Renton S, Leon M, Belcaro G, Nicolaides AN. The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study. Int Angiol 1994;13:259-62.
15. Cesarone MR, Laurora G, Ricci A, Belcaro G, Pomante P, Candiani C, et al. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). Vasa 1992;21:76-80.
16. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-32.
17. Turner RB, Sperber SJ, Sorrentino JV, O'Connor RR, Rogers J, Batouli AR, et al. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin Infect Dis 1997;25:824-30.
18. Gwaltney JM Jr, Druce HM. Efficacy of brompheniramine maleate for the treatment of rhinovirus colds. Clin Infect Dis 1997;25:1188-94.
19. Gwaltney JM Jr, Park J, Paul RA, Edelman DA, O'Connor RR, Turner RB. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis 1996;22:656-62.
20. Dockhorn R, Grossman J, Posner M, Zinny M, Tinkleman D. A double-blind, placebo-controlled study of the safety and efficacy of ipratropium bromide nasal spray versus placebo in patients with the common cold. J Allergy Clin Immunol 1992;90:1076-82.
21. Diamond L, Dockhorn RJ, Grossman J, Kisicki JC, Posner M, Zinny MA, et al. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol 1995;95:1139-46.
22. Hayden FG, Diamond L, Wood PB, Korts DC, Wecker MT. Effectiveness and safety of intranasal ipratropium bromide in common colds: aA randomized, double-blind, placebo-controlled trial. Annals Intern Med 1996;125:89-97.
23. Park YC, Rimbach G, Saliou C, Valacchi G, Packer L, Son JK. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett 2000;465:93-7.
24. Di Carlo A, Passi S, Ippolito F, Candiani C. Free radical scavenger activity of rutosides. Minerva Cardioangiol 2002;50:701-7.
25. Turner RB. The treatment of rhinovirus infections: progress and potential. Antiviral Res 2001;49:1-14.
26. Macknin ML, Piedmonte M, Calendine C, Janosky J, Wald E. Zinc gluconate lozenges for treating the common cold in children. J Am Med Assoc 1998;279:1962-7.
27. Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 1984;25:20-4.
28. Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 1987;20:893-901.
29. Farr BM, Conner EM, Betts RF, Oleske J, Minnefor A, Gwaltney JM Jr. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother 1987;31:1183-7.
30. Godfrey JC, Conant Sloane B, Smith DS, Turco JH, Mercer N, Godfrey NJ. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res 1992;20:234-46.
31. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996;125:81-8.
32. Smith DS, Helzner EC, Nuttall CE Jr, Collins M, Rofman BA, Ginsberg D, et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 1989;33:646-8.
33. Weismann K, Jakobsen JP, Weismann JE, Hammer UM, Nyholm SM, Hansen B, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan Med Bull 1990;37:279-81.
34. Turner RB, Cetnarowski WE. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clin Infect Dis 2000;31:1202-8.
35. Turner RB. Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. Clin Infect Dis 2001;33:1865-70.
36. Hirt M, Nobel S, Barron E. Zinc nasal gel for the treatment of common cold symptoms: a double-blind, placebo-controlled trial. Ear Nose Throat J 2000;79:778-80, 782.